Publicaciones en las que colabora con Begoña Bermejo Fraile (19)

2024

  1. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

2023

  1. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  2. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  3. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

  4. Spatial predictors of immunotherapy response in triple-negative breast cancer

    Nature, Vol. 621, Núm. 7980, pp. 868-876

2022

  1. Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 5, pp. 93-1003

  2. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  3. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

    Annals of Oncology, Vol. 33, Núm. 5, pp. 534-543

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

    Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829

  3. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

    Breast Cancer Research, Vol. 22, Núm. 1

  4. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Nature Communications, Vol. 11, Núm. 1

2019

  1. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

    Annals of Oncology, Vol. 30, Núm. 8, pp. 1289-1297

2018

  1. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 127-138

2015

  1. SEOM clinical guidelines in early-stage breast cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 939-945

2012

  1. Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer

    Journal of Clinical Oncology, Vol. 30, Núm. 13, pp. 1484-1491

2010

  1. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447